Prevents infection by 60-70% from Corona and 70-90% from Influenza
Research conducted by the Korea Disease Control and Prevention Agency “Corona vaccine is 78% effective in preventing severe disease”
Starting on the 11th, influenza and COVID-19 vaccinations will begin for seniors aged 75 and older. Simultaneous vaccination is recommended for high-risk groups as it can greatly reduce the severity rate.
According to the Korea Disease Control and Prevention Agency, seniors over 75 years old and born before December 31, 1949 can receive COVID-19 and influenza vaccines from this day until April 30 of next year. Those aged 70 to 74 can be vaccinated from the 15th of this month, and those aged 65 to 69 can be vaccinated from the 18th.
Both vaccines can be administered at the same time at a medical institution, but health authorities advise people to receive the vaccines at different sites to avoid confusion during vaccination.
An official from the Korea Disease Control and Prevention Agency said, “This is to leave a clear mark because the medical staff may be confused as to whether it was influenza or coronavirus,” and added, “Medically, there is no problem even if it is hit in the same arm.”
The vaccine’s infection prevention effectiveness is known to be about 60-70% for COVID-19 and 70-90% for influenza in healthy adults. There are differences depending on individual immunity, the degree of coincidence between the vaccine and the prevalent virus, etc.
The Korea Disease Control and Prevention Agency is actively urging vaccination, especially for high-risk groups, saying that in addition to preventing infection, the vaccine lowers the risk of serious illness and death.
According to the results of the ‘COVID-19 Vaccine Vaccination Effect Evaluation Study (Professor Choi Jun-yong’s team)’ released by the Korea Disease Control and Prevention Agency in March, those aged 65 or older who received the COVID-19 vaccine ( The effectiveness was found to be 78.1%.
The vaccine used for this vaccination is the JN.1 vaccine (Pfizer, Moderna, Novavax). It is known to be effective against the recently prevalent KP.3 mutation.
Regarding the effectiveness of this vaccine, an official from the Korea Disease Control and Prevention Agency predicted, “We are changing the (type) of the vaccine so that its effectiveness continues to remain at a similar level,” and “It will be at a similar level to what it has been so far.”
Vaccination is recommended for elderly people, but they should not be vaccinated if they have had a severe allergic reaction after a past influenza or coronavirus vaccination or if they have had a severe allergic reaction to a related vaccine ingredient. After vaccination, the injection site may become red and swollen, fever, or muscle pain may occur, but minor adverse reactions will improve within 1 to 2 days.
Designated vaccination medical institutions, such as institutions that can simultaneously vaccinate against coronavirus and influenza, can be searched on the Vaccination Assistant website.
[서울=뉴시스]